Description

Revolade (eltrombopag) Coated Tablets 50 mg. №14

Ingredients:

Each coated tablet contains 50 mg of eltrombopag.

Dosage:

The recommended dosage of Revolade is determined based on the patient’s condition and response to treatment. It is crucial to follow the dosage instructions provided by your healthcare provider.

Indications:

Revolade is indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) and in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.

Contraindications:

Revolade is contraindicated in patients with a history of hypersensitivity to eltrombopag or any component of the formulation.

Directions:

Take Revolade exactly as prescribed by your healthcare provider. Do not adjust the dosage unless instructed to do so. The tablets should be swallowed whole with a glass of water.

Scientific Evidence:

Eltrombopag, the active ingredient in Revolade, is a thrombopoietin receptor agonist that stimulates the production of platelets. Studies have shown that eltrombopag effectively increases platelet counts in patients with chronic ITP and chronic hepatitis C. Research published in the New England Journal of Medicine demonstrated the efficacy of eltrombopag in improving platelet counts and reducing the need for concomitant ITP medications.

Additional Information:

It is important to monitor liver function tests regularly while taking Revolade, as the medication can cause hepatotoxicity. Patients should be educated about the signs of liver problems and instructed to seek medical attention if symptoms such as jaundice, dark urine, or abdominal pain occur. Revolade may interact with certain medications, so it is essential to inform your healthcare provider about all the drugs you are taking.

Overall, Revolade (eltrombopag) coated tablets 50 mg. №14 offer a promising treatment option for patients with thrombocytopenia. The medication’s mechanism of action in stimulating platelet production has shown significant benefits in clinical trials, making it a valuable addition to the management of conditions such as chronic ITP and chronic hepatitis C.